ABCG2 and colorectal cancer: This effect unsurprisingly blocked BCRP expression and subsequently recovered the sensitivity of oxaliplatin-resistant colorectal cancer to oxaliplatin, laying the foundation for the combination of SIT and oxaliplatin [252].